Key result
The ACE2-Ang-(1-7)-Mas receptor axis counteracts the classical ACE-Ang II-AT1 receptor pathway and represents a potential novel therapeutic target for hypertension and kidney disease.
Design
Review
Authors
Loading...
May guide early-phase trials of ACE2-Ang-(1-7)-Mas modulators in hypertension; leaves open clinical adoption pending randomized data.
The ACE2-Ang-(1-7)-Mas receptor axis counteracts the classical RAAS pathway and offers a promising new therapeutic target for managing hypertension and kidney disease.
Ju-Young Moon (2013) conducted a review in Hypertension. The ACE2-Ang-(1-7)-Mas receptor axis counteracts the classical ACE-Ang II-AT1 receptor pathway and represents a potential novel therapeutic target for hypertension and kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: